Compare DexCom, Inc. (DXCM) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Verisign, Inc. — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Verisign, Inc. trades at $277.24 (market cap $24.62B). The key difference: DexCom, Inc. and Verisign, Inc. are close in size by market cap, and Verisign, Inc. pays a 1.2% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | VRSN | |
|---|---|---|
Market Cap | $28.06B | $24.62B |
Sector | Health | Technology |
52-Week High | $89.53 | $310.00 |
52-Week Low | $54.84 | $211.49 |
Enterprise Value | $27.03B | $25.86B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
VeriSign (VRSN) is trading at $276.67, up 2.91% today, with a bullish technical signal from moving averages and strong fundamentals including a 49.96% net income margin and consistent revenue growth to $1.66B in 2025. Recent Q1 2026 earnings beat expectations at $2.34 EPS, and the company maintains a dominant position as the registry for .com and .net domains, supported by AI-driven registration growth.
The outlook is positive with a consensus price target of $325.25, representing 17.6% upside, though risks include contract renewal uncertainty and high valuation multiples. Analyst sentiment is bullish with 57% buy ratings, but investors should monitor AI disruption potential and the upcoming Q2 2026 earnings report for further direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
